Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Yutaka_Niihara
|
| gptkbp:focus |
rare diseases
sickle cell disease |
| gptkbp:foundedYear |
2003
|
| gptkbp:founder |
gptkb:Yutaka_Niihara
|
| gptkbp:headquartersLocation |
gptkb:Torrance,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Emmaus Medical
|
| gptkbp:industry |
biopharmaceuticals
|
| gptkbp:notableApproval |
FDA approval for Endari in 2017
|
| gptkbp:product |
gptkb:Endari
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:OTC_Markets
|
| gptkbp:stockSymbol |
gptkb:EMMA
|
| gptkbp:website |
https://www.emmausmedical.com/
|
| gptkbp:bfsParent |
gptkb:Endari
|
| gptkbp:bfsLayer |
7
|